SCHEMBL2368544

SCHEMBL2368544

Cc1sc2nc(C(CO)CO)nc(NCc3ccccn3)c2c1-c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 10/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
KCNH2 Q12809 8/20 0.41
PRKCI P41743 1/20 0.40
TNF P01375 1/20 0.37
MAPK1 P28482 1/20 0.37
NOD1 Q9Y239 1/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
JAK2 O60674 2/20 0.37
CDK2 P24941 2/20 0.37
TYK2 P29597 2/20 0.37
GSK3B P49841 2/20 0.37
JAK3 P52333 2/20 0.37
BTK Q06187 2/20 0.37
AURKB Q96GD4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368976 0.93 KCNH2 (0.48) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2369569 0.88 PRKCI (0.37) KCNA5MEN1KMT2APRKCIJAK2
Butane SCHEMBL6359344 0.85 SMN1; SMN2 (0.41) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2368411 0.85 SMN1; SMN2 (0.42) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2369248 0.84 KCNA5 (0.45) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2368771 0.84 CLK4 (0.47) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2368909 0.84 KCNA5 (0.44) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2369260 0.82 TNF (0.55) KCNA5SMN1; SMN2KCNH2TNFMAPK1
SCHEMBL2368637 0.82 KCNA5 (0.43) KCNA5MEN1KMT2ASMN1; SMN2KCNH2
SCHEMBL2368869 0.81 PRKCI (0.43) KCNA5SMN1; SMN2KCNH2PRKCICSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 KCNA5 8/4885MEN1 265/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.